Medscape_Oncology_whiteout

The Reality of Care for HER2-Mutated Advanced NSCLC

Closing Community Gaps CME

Hilton Chicago

Saturday, May 30, 2026 | 6:15 pm - 7:45 pm CT

Hybrid

Supported by an independent educational grant from Bayer.

overview

Join our distinguished panel of experts for a dynamic and engaging symposium that deep dives into the latest cutting-edge developments for [italic]HER2[/italic]-mutated non-small cell lung cancer. Gain mastery of molecular testing and implementation of evidenced-based strategies with HER2-directed therapies to personalize treatment and ease the burden of disease.

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.

faculty

agenda

6:00 PM CT

6:15 PM CT

6:20 PM CT

6:35 PM CT

6:55 PM CT

7:20 PM CT

7:35 PM CT

location

Hilton Chicago

720 S Michigan Ave, Chicago, Illinois, 60605

Room: International Ballroom South (2nd Floor)

target audience

This activity is intended for an international audience of oncologists, pathologists, pulmonologists, nurses, nurse practitioners, and physician assistants.

goal statement

The goal of this activity is for learners to be better able to integrate novel therapies for [italic]HER2[/italic]-mutated advanced non-small cell lung cancer (NSCLC) into clinical practice.

learning objectives

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Latest clinical evidence on novel and emerging treatment for [italic]HER2[/italic]-mutated advanced NSCLC [item]Best practices for [italic]HER2[/italic] testing in patients with NSCLC [/list] [para]Have greater competence related to[/para] [list][item]Tailoring treatment for patients with [italic]HER2[/italic]-mutated advanced NSCLC [/list] [para]Demonstrate greater confidence in their ability to [/para] [list][item] Work within the multidisciplinary team in identifying patients with [italic]HER2[/italic]-mutated NSCLC who may benefit from novel targeted therapies [/list]

accreditation statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

accreditation logo
medscape logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.5 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text]